Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarker Driven and Dose Intensified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk Diffuse Large B-Cell Lymphoma

NCT03293173 is registered in ClinicalTrials.gov with Nordic Lymphoma Group as lead sponsor.

NCT NCT03293173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03293173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarker Driven and Dose Intensified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk Diffuse Large B-Cell Lymphoma
Lead sponsor
Nordic Lymphoma Group
Phase
Phase 2
Overall status
Unknown status
Start date
August 4, 2017
Completion date
December 31, 2024
Enrollment
120 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, large b-cell, diffuse